SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19
Top Cited Papers
- 30 September 2020
- journal article
- research article
- Published by Elsevier BV in Food and Chemical Toxicology
- Vol. 146, 111769
- https://doi.org/10.1016/j.fct.2020.111769
Abstract
No abstract availableKeywords
Funding Information
- National Institute of Environmental Health Sciences (R01ES07331, R01ES10563)
This publication has 218 references indexed in Scilit:
- Perforin-dependent CD4+T-cell cytotoxicity contributes to control a murine poxvirus infectionProceedings of the National Academy of Sciences of the United States of America, 2012
- Therapeutic perspective: starting an angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in a diabetic patientTherapeutic Advances in Endocrinology and Metabolism, 2010
- SARS‐coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARSEuropean Journal of Clinical Investigation, 2009
- Modulation of TNF-α-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-α production and facilitates viral entryProceedings of the National Academy of Sciences of the United States of America, 2008
- ACE2 Receptor Expression and Severe Acute Respiratory Syndrome Coronavirus Infection Depend on Differentiation of Human Airway EpitheliaJournal of Virology, 2005
- Acute renal impairment in coronavirus-associated severe acute respiratory syndromeKidney International, 2005
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson's diseaseMovement Disorders, 1992
- Chemotherapy-induced immunosuppression.Environmental Health Perspectives, 1982